insulin

[Gan & Lee Pharmaceuticals Co., Ltd.] Gan & Lee Pharmaceuticals Co., Ltd. announced that the US FDA has cleared the Investigational New Drug application for the company’s compound, GZR18, to improve the management of type 2 diabetes mellitus.

[eLife] Researchers indicate that microtubules (MTs) stability in the β-cell population was heterogenous, and that glucose-stimulated insulin secretion was suppressed in cells with highly stable MTs.

[Journal of Clinical Investigation] The authors provided new insights into the mechanisms that underlied Dyrk1b-induced hepatic lipogenesis and hepatic insulin resistance and identified Dyrk1b as a therapeutic target for non-alcoholic liver steatohepatitis and insulin resistance in the liver.

[Cellular & Molecular Immunology] Investigators review the key findings that have shaped our understanding of how immune cells regulate adipose tissue homeostasis to control organismal metabolism.

[Cell Stem Cell] The authors reported an analysis on one year of data from the first cohort of 15 patients from a single trial site that received subcutaneous implantation of cell products combined with an immunosuppressive regimen.

[Nature Communications] Investigators showed GP73, a Golgi protein upregulated in livers from patients with a variety of liver diseases, exhibits Rab GTPase-activating protein activity regulating ApoB export.